沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察

doi:10.19401/j.cnki.1007-3639.2017.04.008

中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (4): 287-292.doi: 10.19401/j.cnki.1007-3639.2017.04.008

沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察

冯　静¹，廖绍光¹，程惠华¹，傅志超¹，骆华春¹，应文敏¹，周进平²

1. 南京军区福州总医院放疗科，福建福州 350025 ；
2. 南京军区福州总医院医务部，福建福州 350025

出版日期:2017-04-30 发布日期:2017-05-05
通信作者: 周进平　E-mail: zhoujinping@163.com
基金资助:
福建省自然科学基金资助项目(2016J05198)；中华医学基金会(314·2213)；福建医科大学启航基金(2016QH129)。

Clinical outcome of castrate-resistant prostate cancer patients with bone metastasis treated with thalidomide combined with docetaxel

FENG Jing¹, LIAO Shaoguang¹, CHENG Huihua¹, FU Zhichao¹, LUO Huachun¹, YING Wenmin¹, ZHOU Jinping²

1. Department of Radiation Oncology, Fuzhou General Hospital of Nanjing Command, PLA, Fuzhou 350025, Fujian Province, China; 2. Department of Medical Administration, Fuzhou General Hospital of Nanjing Command, PLA, Fuzhou 350025, Fujian Province, China

Published:2017-04-30 Online:2017-05-05
Contact: ZHOU Jinping E-mail: zhoujinping@163.com

摘要/Abstract

摘要： 背景与目的：多西他赛联合泼尼松治疗可延长转移性去势抵抗性前列腺癌患者的生存期，血管生成抑制剂也可抑制肿瘤生长，联合治疗的疗效目前仍不明确。该研究旨在观察沙利度胺联合多西他赛和泼尼松治疗骨转移的去势抵抗性前列腺癌的近期临床疗效。方法：收集2008年12月—2015年6月南京军区福州总医院收治的骨转移去势抵抗性前列腺癌患者78例，其中40例作为对照组给予多西他赛和泼尼松方案化疗，38例作为观察组在对照组的基础上给予沙利度胺联合化疗，观察两组有效率、骨痛缓解率、前列腺特异性抗原(prostate specific antigen，PSA)无进展时间、无疾病进展时间及总生存时间，并评价不良反应。结果：观察组有效率为65.79%，PSA无进展时间为4.13个月，无疾病进展时间为4.25个月，骨痛缓解率为86.84%；对照组有效率为40.00%，PSA无进展时间为3.54个月，无疾病进展时间为3.75个月，骨痛缓解率为60.00%，观察组均高于对照组，差异有统计学意义(P<0.05)。治疗后两组总生存时间、患者恶心呕吐及白细胞下降等不良反应发生率比较，差异无统计学意义(P>0.05)。结论：沙利度胺联合化疗治疗骨转移的去势抵抗性前列腺癌近期临床效果满意，安全，不增加不良反应，具有较高的临床应用价值。

关键词: 去势抵抗性前列腺癌, 骨转移, 沙利度胺, 化疗

Abstract: Background and purpose: Docetaxel plus prednisone chemotherapy can improve the patients’ survival for castrate-resistant prostate cancer. Angiogenesis inhibitors can also inhibit the growth of tumor. The curative effect of combined treatment is still not clear. This study aimed to evaluate the efficacy of docetaxel plus prednisone combined with thalidomide in treating castrate-resistant prostate cancer (CRPC) patients with bone metastasis. Methods: A total number of 78 CRPC patients were selected in Fuzhou General Hospital from Dec. 2008 to Jun. 2015. Seventy-eight patients were divided into two groups: 40 patients in chemotherapy group (docetaxel plus prednisone) and 38 patients in combined treatment group (docetaxel plus prednisone combined with thalidomide). A total number of 78 subjects were evaluated by the effective rate, the remission rate of bone pain, the prostate specific antigen (PSA) progression-free survival, the overall survival and adverse effect. Results: The response rate (65.79%) and the remission rate of bone pain (86.84%) in combined treatment group were both higher than those in chemotherapy group (40.00% and 60.00%, P<0.05). The PSA progression-free survival (4.13 months), progression-free survival (4.25 months) and the overall survival (18.06 months) in combined treatment group were all longer than those in chemotherapy group (3.54, 3.75 and 16.26 months). The PSA pro-gression-free survival was significantly longer in combined treatment group (P<0.05). There was no significant difference in the overall survival between two groups (P>0.05). The rates of adverse effects including peripheral neuritis and lethargy in combined treatment group (26.32% and 55.26%) were higher than those in chemotherapy group (5.00% and 17.50%, P<0.05). Conclusion: Thalidomide combined with docetaxel plus prednisone in CRPC patients with bone metastasis can prolong the PSA progression-free survival and overall survival. The adverse effects are mild. It may become a new choice of
treatment for CRPC.

Key words: Castrate-resistant prostate cancer, Thalidomide, Bone metastasis, Chemotherapy

冯　静,廖绍光,程惠华,等. 沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察[J]. 中国癌症杂志, 2017, 27(4): 287-292.

FENG Jing, LIAO Shaoguang, CHENG Huihua, et al. Clinical outcome of castrate-resistant prostate cancer patients with bone metastasis treated with thalidomide combined with docetaxel[J]. China Oncology, 2017, 27(4): 287-292.

[1]	陆　立, 卢仁泉, 孙佳俊, 陆　凝, 郭　林. 血清N-MID在原发性肺癌患者骨转移辅助诊断和疗效监测中的应用分析[J]. 中国癌症杂志, 2021, 31(9): 838-844.
[2]	朱　俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4): 250-256.
[3]	蔡树模, 汤　洁, 黄　啸, 黄晓炜, 刘素萍, 柯桂好, 郑　重, 程　玺, 唐美琴. 铂类药物敏感复发卵巢癌患者的三步化疗法附20例分析[J]. 中国癌症杂志, 2021, 31(4): 330-334.
[4]	王　铸, 张　颖, 张建文, 邓　琼, 梁　辉. 核受体HNF4α通过调控雄激素受体表达促进去势抵抗性前列腺癌进展[J]. 中国癌症杂志, 2021, 31(3): 170-175.
[5]	胡喜娥, 杨振宇, 薛景毅, 杨　平, 彭书甲, 袁利娟, 包国强 . 单细胞测序在三阴性乳腺癌新辅助化疗中的应用研究进展[J]. 中国癌症杂志, 2021, 31(3): 221-226.
[6]	何合胜, 杨玉琼, 刘银华, 靳小可, 徐又海, 姚军萍, 刘善浩, 严家炜, 黄东平 . 外周T细胞淋巴瘤合并自身免疫性溶血性贫血的临床特点分析[J]. 中国癌症杂志, 2021, 31(2): 121-125.
[7]	李　磊, 王　智, 由春媛 . 原发性心脏高级别B细胞淋巴瘤化疗缓解后复发1例报告[J]. 中国癌症杂志, 2021, 31(2): 156-160.
[8]	李盼盼, 张　卓. 42例原发性中枢神经系统淋巴瘤患者预后影响因素分析[J]. 中国癌症杂志, 2021, 31(12): 1194-1201.
[9]	卢大松, 冯勇军, 王武峰, 牟忠林, 赵　娜. 个体化营养干预对局部晚期鼻咽癌患者生活质量及生存预后的影响[J]. 中国癌症杂志, 2021, 31(12): 1202-1208.
[10]	俞　弋, 丛　青, 徐丛剑, 姜　伟. PAFR对卵巢癌细胞顺铂敏感性的影响及机制研究[J]. 中国癌症杂志, 2021, 31(11): 1063-1071.
[11]	刘加葳, 李　丹, 翟　青. 乳腺癌患者化疗致肝损伤的危险因素分析[J]. 中国癌症杂志, 2021, 31(1): 52-62.
[12]	张晓萌 , 麻宁一 , 祝鸿程 , 艾沓杉 , 任志刚 . 胰腺癌术后辅助性放化疗的效果及预后因素分析[J]. 中国癌症杂志, 2020, 30(7): 519-524.
[13]	吴婧文, 于学娟, 杨秋安. 小野寺预后营养指数与食管鳞癌同步放化疗不良反应的相关性研究[J]. 中国癌症杂志, 2020, 30(7): 525-530.
[14]	石志强 , 邱鹏飞 , 刘雁冰 , 赵　桐 , 孙　晓 , 陈　鹏 , 王春建 , 张朝蓬 , 丛斌斌 , 王永胜 . HER2阳性和三阴性乳腺癌新辅助化疗后选择性避免腋窝手术分期的研究[J]. 中国癌症杂志, 2020, 30(3): 186-191.
[15]	宁周雨, 花永强, 徐立涛, 庄丽萍, 冯兰云, 陈　颢, 王　鹏, 沈晔华, 林钧华, 陈　震, 孟志强. 白蛋白结合型紫杉醇联合吉西他滨动脉灌注治疗进展期胰腺癌的安全性和有效性回顾性研究[J]. 中国癌症杂志, 2020, 30(2): 128-134.

沙利度胺联合化疗治疗骨转移去势抵抗性前列腺癌的疗效观察

Clinical outcome of castrate-resistant prostate cancer patients with bone metastasis treated with thalidomide combined with docetaxel

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价